India, Nov. 10 -- Protalix BioTherapeutics, Inc. (PLX) reported higher third-quarter 2026 net income and strong year-to-date revenue growth Tuesday, while reaffirming its full-year revenue outlook.
The company also provided updates on its investigational PRX-115 program for uncontrolled gout, with Phase 2 results expected in the second half of 2027.
Company Profile
Protalix is a biopharmaceutical company developing and commercializing treatments for rare diseases. Its portfolio includes Elfabrio for Fabry disease and Elelyso for Gaucher disease, along with investigational candidates developed using its proprietary ProCellEx plant cell-based protein expression platform.
Third-Quarter 2026 Financial Results
For the quarter ended Septembe...